News
A lab's interpretation that an STK11 variant of uncertain significance is likely pathogenic supports a young woman's ...
Steroids May Obscure Predictive Power of Circulating Biomarkers in Lung Cancer Patients, Study Finds
A recent paper has shed more light on how corticosteroids frequently prescribed to lung cancer patients could inhibit the ...
Can Scientists Develop Drugs for Genetic Diseases by Studying Those Who Should Have Them, but Don't?
Researchers led by the nonprofit 4YouandMe and Mount Sinai want to identify second-site suppressor mutations as drug targets ...
Researchers hope to test the product's ability to clear symptoms in patients with the rare genetic disorder driven by RPS19 ...
The company is testing its lead asset, a CAR T/NK-cell therapy, in a Phase I trial in patients with B-cell malignancies.
NEW YORK – Kelonia Therapeutics this week said it has started treating patients with relapsed and refractory multiple myeloma in a Phase I trial of its in vivo CAR T-cell therapy KLN-1010.
The latest report from the Make-an-IMPACT program focused on results delivered for pediatric cancer patients across 11 ...
NEW YORK – Krystal Biotech has discontinued a Phase I/II clinical trial evaluating an injected version of its gene therapy KB707 in locally advanced or metastatic solid tumors, including melanoma.
ALX hopes to gain insights by tracking EGFR expression in a new trial of ALX2004 and to identify best responders using CD47 expression in a trial of evorpacept.
The firm will evaluate its EGFR-targeted ADC ALX2004 in advanced non-small cell lung, head and neck, esophageal, and colorectal cancers.
The antisense oligonucleotide is a prophylactic treatment for preventing swelling attacks due to hereditary angioedema.
The firm is advancing ELI-002 after seeing a positive Phase I readout this month and is expecting initial results from a randomized Phase II study this year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback